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Myostatin (MSTN) is a transforming growth factor-β (TGF-β) family
member that normally acts to limit muscle growth. The function of
MSTN is partially redundant with that of another TGF-β family
member, activin A. MSTN and activin A are capable of signaling
through a complex of type II and type I receptors. Here, we inves-
tigated the roles of two type II receptors (ACVR2 and ACVR2B) and
two type I receptors (ALK4 and ALK5) in the regulation of muscle
mass by these ligands by genetically targeting these receptors ei-
ther alone or in combination specifically in myofibers in mice. We
show that targeting signaling in myofibers is sufficient to cause
significant increases in muscle mass, showing that myofibers are
the direct target for signaling by these ligands in the regulation of
muscle growth. Moreover, we show that there is functional redun-
dancy between the two type II receptors as well as between the
two type I receptors and that all four type II/type I receptor com-
binations are utilized in vivo. Targeting signaling specifically in
myofibers also led to reductions in overall body fat content and
improved glucose metabolism in mice fed either regular chow or a
high-fat diet, demonstrating that these metabolic effects are the
result of enhanced muscling. We observed no effect, however, on
either bone density or muscle regeneration in mice in which sig-
naling was targeted in myofibers. The latter finding implies that
MSTN likely signals to other cells, such as satellite cells, in addition
to myofibers to regulate muscle homeostasis.
myostatin | activin | receptors | skeletal muscle
Myostatin (MSTN) is a secreted signaling molecule thatnormally acts to limit skeletal muscle growth (for review,
see ref. 1). Mice lacking MSTN exhibit dramatic increases in
muscle mass throughout the body, with individual muscles
growing to about twice the normal size (2). MSTN appears to
play two distinct roles in regulating muscle size, one to regulate
the number of muscle fibers that are formed during development
and a second to regulate the growth of those fibers postnatally.
The sequence of MSTN has been highly conserved through
evolution, with the mature MSTN peptide being identical in
species as divergent as humans and turkeys (3). The function of
MSTN has also been conserved, and targeted or naturally oc-
curring mutations in MSTN have been shown to cause increased
muscling in numerous species, including cattle (3–5), sheep (6),
dogs (7), rabbits (8), rats (9), swine (10), goats (11), and humans
(12). Numerous pharmaceutical and biotechnology companies
have developed biologic agents capable of blocking MSTN ac-
tivity, and these have been tested in clinical trials for a wide
range of indications, including Duchenne and facioscapulo-
humeral muscular dystrophy, inclusion body myositis, muscle
atrophy following falls and hip fracture surgery, age-related sarco-
penia, Charcot–Marie–Tooth disease, and cachexia due to chronic
obstructive pulmonary disease, end-stage kidney disease, and cancer.
The finding that certain inhibitors of MSTN signaling can
increase muscle mass even in Mstn−/− mice revealed that the
function of MSTN as a negative regulator of muscle mass is
partially redundant with at least one other TGF-β family member
(13, 14), and subsequent studies have identified activin A as one
of these cooperating ligands (15, 16). MSTN and activin A share
many key regulatory and signaling components. For example, the
activities of both MSTN and activin A can be modulated extra-
cellularly by naturally occurring inhibitory binding proteins, in-
cluding follistatin (17, 18) and the follistatin-related protein,
FSTL-3 or FLRG (19, 20). Moreover, MSTN and activin A also
appear to share receptor components. Based on in vitro studies,
MSTN is capable of binding initially to the activin type II re-
ceptors, ACVR2 and ACVR2B (also called ActRIIA and
ActRIIB) (18) followed by engagement of the type I receptors,
ALK4 and ALK5 (21). In previous studies, we presented genetic
evidence supporting a role for both ACVR2 and ACVR2B in
mediating MSTN signaling and regulating muscle mass in vivo.
Specifically, we showed that mice expressing a truncated,
dominant-negative form of ACVR2B in skeletal muscle (18) or
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carrying deletion mutations in Acvr2 and/or Acvr2b (13) have
significantly increased muscle mass. One limitation of the latter
study, however, was that we could not examine the consequence
of complete loss of both receptors using the deletion alleles, as
double homozygous mutants die early during embryogenesis
(22). Moreover, the roles that the two type I receptors, ALK4
and ALK5, play in regulating MSTN and activin A signaling in
muscle in vivo have not yet been documented using genetic ap-
proaches. Here, we present the results of studies in which we
used floxed alleles for each of the type II and type I receptor
genes in order to target these receptors alone and in combination
in muscle fibers. We show that these receptors are functionally
redundant and that signaling through each of these receptors
contributes to the overall control of muscle mass.
Results
To determine the effect of targeting the two known type II re-
ceptors for MSTN specifically in skeletal muscle, we generated
mice carrying floxed alleles for both Acvr2 and Acvr2b (23, 24)
and then targeted these alleles using a transgene expressing cre
recombinase from a myosin light chain promoter/enhancer
(Myl1-cre) (25), which we showed to be expressed by skeletal
muscle fibers but not by satellite cells (23). Quantification of
receptor messenger RNA (mRNA) levels in various muscles
showed that we were able to reduce expression significantly in
each of the floxed lines, with the residual expression likely rep-
resenting RNA made either by type I fibers or by nonmuscle cells
(SI Appendix, Fig. S1). Significantly, in mice in which a given
receptor was targeted in muscle, expression levels of each of the
other receptors were relatively unchanged, indicating that there
was not a compensatory up-regulation of expression of any of the
other receptors.
As we reported previously (23), targeting Acvr2b alone in
muscle fibers resulted in increases in muscle mass of about 8 to
12% in females and about 4 to 6% in males depending on the
specific muscle examined (Fig. 1A and Table 1). Targeting Acvr2
alone resulted in similar, statistically significant increases in the
quadriceps and gastrocnemius but not in the pectoralis or tri-
ceps. Targeting both receptors simultaneously resulted in much
more substantial increases in all muscles examined, with the
greatest effect being seen in the quadriceps (58 and 50% in fe-
males and males, respectively) and gastrocnemius (72 and 62%
in females and males, respectively). These results show defini-
tively that Acvr2 and Acvr2b are functionally redundant with one
another with respect to limiting muscle mass and that targeting
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Fig. 1. Effect of targeting type II and type I receptors in myofibers on muscle weights. (A and B) Relative weights of pectoralis (red), triceps (gray), quadriceps
(blue), and gastrocnemius/plantaris (green) muscles in mice in which Acvr2 and/or Acvr2b (A) or Alk4 and/or Alk5 (B) were targeted. Numbers are expressed as
percent increase/decrease relative to the same receptor genotypes but in the absence of Myl1-cre. (C) Gastrocnemius/plantaris muscle weights of individual
wild-type C57BL/6 andMstn−/− mice or individual mice in which Acvr2/Acvr2b or Alk4/Alk5were targeted in myofibers. Bars indicates mean values. (D) Relative
muscle weights of mice in which an individual type II receptor (Acvr2 or Acvr2b) was targeted along with an individual type I receptor (Alk4 or Alk5). (E and F)
Relative muscle weights of mice in which an individual type II or type I receptor was targeted along with Cfc1b (E) or Mstn (F). Numbers are expressed as
percent increase/decrease relative to the same receptor genotypes but in the absence of Myl1-cre, and the color code is the same as in A and B. The numbers
shown in A, B, D, and F were calculations based on muscle weights shown in Tables 1–3, which also contain the numbers of mice in each group. aP < 0.001 vs.
cre−; bP < 0.01 vs. cre−; cP < 0.05 vs. cre−; dP < 0.001 vs. Mstn fl/fl, cre+; eP < 0.01 vs. Mstn fl/fl, cre+; fP < 0.05 vs. Mstn fl/fl, cre+.


























muscle growth, confirming the conclusions from our earlier
studies that myofibers are the primary direct target for signaling
by MSTN in the regulation of muscle growth (23).
In vitro studies have suggested that binding of MSTN to
ACVR2 and/or ACVR2B leads to engagement of the type I
receptors ALK4 and ALK5 (21). To provide genetic support for
roles of these type I receptors in mediating MSTN signaling
in vivo, we analyzed the effect of targeting Alk4 and Alk5 spe-
cifically in myofibers. For Alk4, we generated a mouse line in
which we flanked exons 2 to 3 with LoxP sites (SI Appendix, Fig.
S2); removal of these exons by cre recombinase would be pre-
dicted to delete the entire ligand-binding and transmembrane
domains and result in a null allele. For Alk5, we utilized a floxed
Alk5 line that had been described previously (26). As in the case
of the type II receptors, the Myl1-cre transgene significantly re-
duced RNA levels for both Alk4 and Alk5 in muscle (SI Ap-
pendix, Fig. S1). Targeting Alk4 or Alk5 in myofibers resulted in
statistically significant effects on muscle mass, ranging from up to
Table 1. Muscle weights
Acvr2 Acvr2b Alk4 Alk5 Bmpr2 cre n Pectoralis, mg Triceps, mg Quadriceps, mg Gastrocnemius, mg
Males
fl/fl +/+ +/+ +/+ +/+ − 17 64.1 ± 1.1 86.4 ± 1.2 170.2 ± 2.0 122.9 ± 1.6
fl/fl +/+ +/+ +/+ +/+ + 14 61.0 ± 1.9 83.9 ± 1.8 176.6 ± 2.8 130.7 ± 2.2*
+/+ fl/fl +/+ +/+ +/+ − 31 64.9 ± 1.1 90.3 ± 1.2 180.7 ± 2.1 127.9 ± 1.5
+/+ fl/fl +/+ +/+ +/+ + 21 69.0 ± 1.2† 94.2 ± 1.6† 188.1 ± 2.8† 133.2 ± 1.8†
+/+ +/+ fl/fl +/+ +/+ − 19 76.4 ± 1.4 98.1 ± 1.5 192.8 ± 2.6 137.4 ± 2.0
+/+ +/+ fl/fl +/+ +/+ + 11 74.4 ± 2.0 96.3 ± 1.9 199.1 ± 3.5 139.4 ± 3.3
+/+ +/+ +/+ fl/fl +/+ − 16 72.3 ± 2.2 97.4 ± 2.6 196.1 ± 5.6 129.3 ± 3.2
+/+ +/+ +/+ fl/fl +/+ + 18 75.7 ± 2.5 100.9 ± 3.4 217.3 ± 6.9† 152.2 ± 5.1‡
fl/fl fl/fl +/+ +/+ +/+ − 13 60.4 ± 1.8 83.3 ± 2.1 167.4 ± 3.5 120.8 ± 2.2
fl/fl fl/fl +/+ +/+ +/+ + 16 67.3 ± 1.6* 118.9 ± 3.9‡ 250.3 ± 6.3‡ 195.6 ± 4.1‡
+/+ +/+ fl/fl fl/fl +/+ − 13 72.5 ± 1.8 93.8 ± 1.7 183.5 ± 3.6 131.5 ± 2.5
+/+ +/+ fl/fl fl/fl +/+ + 11 54.6 ± 4.1‡ 160.0 ± 13.4‡ 433.1 ± 25.1‡ 390.0 ± 29.1‡
fl/fl +/+ fl/fl +/+ +/+ − 14 72.4 ± 1.3 95.0 ± 1.6 182.9 ± 3.2 135.4 ± 1.6
fl/fl +/+ fl/fl +/+ +/+ + 15 70.9 ± 1.7 99.0 ± 2.5 207.1 ± 6.1* 152.9 ± 3.9‡
+/+ fl/fl fl/fl +/+ +/+ − 13 76.3 ± 2.0 98.1 ± 1.9 191.2 ± 3.8 136.4 ± 3.1
+/+ fl/fl fl/fl +/+ +/+ + 13 80.2 ± 1.8 107.8 ± 2.0‡ 218.1 ± 4.6‡ 150.8 ± 3.3*
fl/fl +/+ +/+ fl/fl +/+ − 16 69.6 ± 2.3 93.5 ± 2.4 187.8 ± 6.2 129.6 ± 3.6
fl/fl +/+ +/+ fl/fl +/+ + 10 72.4 ± 2.5 106.2 ± 3.8* 255.9 ± 9.0‡ 188.4 ± 9.9‡
+/+ fl/fl +/+ fl/fl +/+ − 18 77.3 ± 2.3 105.7 ± 3.0 210.2 ± 6.1 141.4 ± 3.6
+/+ fl/fl +/+ fl/fl +/+ + 18 87.0 ± 3.0† 119.3 ± 3.2* 255.1 ± 6.1‡ 180.7 ± 4.4‡
+/+ +/+ +/+ +/+ fl/fl − 15 83.1 ± 2.0 106.5 ± 2.7 213.9 ± 4.7 148.7 ± 3.2
+/+ +/+ +/+ +/+ fl/fl + 11 79.8 ± 3.0 105.5 ± 4.1 196.4 ± 5.6† 138.4 ± 3.8†
fl/fl fl/fl +/+ +/+ fl/fl − 5 71.8 ± 2.6 96.4 ± 4.5 178.6 ± 9.3 131.4 ± 6.0
fl/fl fl/fl +/+ +/+ fl/fl + 6 81.2 ± 4.3 133.2 ± 9.5* 242.7 ± 11.8* 198.0 ± 3.4‡
Females
fl/fl +/+ +/+ +/+ +/+ − 17 43.0 ± 1.0 66.1 ± 1.3 132.8 ± 2.7 94.8 ± 1.6
fl/fl +/+ +/+ +/+ +/+ + 15 41.5 ± 0.9 66.5 ± 1.0 143.7 ± 2.9* 102.8 ± 1.2‡
+/+ fl/fl +/+ +/+ +/+ − 20 45.7 ± 0.9 70.0 ± 1.2 142.9 ± 2.4 99.3 ± 1.7
+/+ fl/fl +/+ +/+ +/+ + 34 51.2 ± 0.8‡ 76.4 ± 1.2‡ 153.8 ± 2.2* 107.6 ± 1.4‡
+/+ +/+ fl/fl +/+ +/+ − 19 50.8 ± 1.0 73.0 ± 1.0 143.4 ± 2.0 102.7 ± 1.4
+/+ +/+ fl/fl +/+ +/+ + 27 53.7 ± 1.5 77.2 ± 1.8† 158.4 ± 2.9‡ 111.4 ± 2.3‡
+/+ +/+ +/+ fl/fl +/+ − 14 43.9 ± 1.5 68.3 ± 1.9 136.3 ± 3.7 91.2 ± 1.7
+/+ +/+ +/+ fl/fl +/+ + 19 47.0 ± 1.1 74.1 ± 1.8† 150.3 ± 3.7* 105.2 ± 2.7‡
fl/fl fl/fl +/+ +/+ +/+ − 11 41.1 ± 1.2 65.8 ± 1.7 128.2 ± 3.6 90.8 ± 2.4
fl/fl fl/fl +/+ +/+ +/+ + 15 52.7 ± 1.8‡ 93.6 ± 2.5‡ 202.6 ± 5.8‡ 156.3 ± 5.6‡
+/+ +/+ fl/fl fl/fl +/+ − 14 50.1 ± 1.5 70.4 ± 1.6 142.2 ± 3.0 97.4 ± 1.9
+/+ +/+ fl/fl fl/fl +/+ + 9 43.4 ± 3.5 156.9 ± 27.9† 387.9 ± 60.3* 339.9 ± 52.0*
fl/fl +/+ fl/fl +/+ +/+ − 10 48.4 ± 0.9 71.2 ± 1.1 144.7 ± 2.4 105.7 ± 1.9
fl/fl +/+ fl/fl +/+ +/+ + 13 48.8 ± 1.5 73.8 ± 1.1 156.4 ± 3.5* 115.5 ± 2.9*
+/+ fl/fl fl/fl +/+ +/+ − 24 53.5 ± 0.9 75.8 ± 1.3 150.5 ± 2.5 106.8 ± 1.6
+/+ fl/fl fl/fl +/+ +/+ + 20 59.0 ± 1.2‡ 83.5 ± 1.5‡ 174.1 ± 2.4‡ 121.7 ± 1.6‡
fl/fl +/+ +/+ fl/fl +/+ − 15 45.7 ± 1.2 65.7 ± 1.4 131.7 ± 2.5 89.7 ± 1.8
fl/fl +/+ +/+ fl/fl +/+ + 17 47.5 ± 1.1 79.6 ± 2.5‡ 181.5 ± 5.1‡ 129.8 ± 3.3‡
+/+ fl/fl +/+ fl/fl +/+ − 20 44.9 ± 0.8 68.3 ± 1.4 137.9 ± 2.4 93.9 ± 2.0
+/+ fl/fl +/+ fl/fl +/+ + 18 56.3 ± 1.6‡ 81.8 ± 1.4‡ 174.6 ± 3.6‡ 121.7 ± 3.2‡
+/+ +/+ +/+ +/+ fl/fl − 17 50.3 ± 1.3 74.2 ± 1.9 146.9 ± 3.1 101.1 ± 2.2
+/+ +/+ +/+ +/+ fl/fl + 20 46.5 ± 1.1† 68.9 ± 1.3† 133.8 ± 2.6* 87.9 ± 3.5*
fl/fl fl/fl +/+ +/+ fl/fl − 8 48.6 ± 1.6 71.8 ± 2.0 140.0 ± 4.2 100.9 ± 3.1
fl/fl fl/fl +/+ +/+ fl/fl + 5 50.4 ± 2.1 100.4 ± 11.1† 184.6 ± 6.3‡ 156.4 ± 8.2‡
*P < 0.01 vs. cre−.
†P < 0.05 vs. cre−.
‡P < 0.001 vs. cre−.











































11% in the case of Alk4 and up to 18% in the case of Alk5,
depending on the sex of the mice and the specific muscles ex-
amined (Fig. 1B and Table 1). As in the case of the type II re-
ceptors, targeting both type I receptors simultaneously resulted
in much more substantial increases, with the greatest effects
being seen in the quadriceps (173 and 136% in females and
males, respectively) and gastrocnemius (249 and 197% in fe-
males and males, respectively). These increases were even more
pronounced than those seen in Mstn−/− mice and more remi-
niscent of the magnitude of effects seen upon targeting multiple
ligands (14). These results demonstrate that both ALK4 and
ALK5 play critical roles in limiting skeletal muscle mass in vivo,
that these two receptors are functionally redundant in muscle,
and that together, they regulate signaling by multiple ligands in
myofibers, most likely MSTN and activin A.
The increases seen upon targeting the two type I receptors
were much more extensive than those seen upon targeting the
two type II receptors. This finding raised the possibility that
another type II receptor may be utilized in addition to ACVR2
and ACVR2B. One possible candidate was BMPRII, although
we were unable to detect significant binding of MSTN to
BMPRII in transfected cells (18). Moreover, a previous study
suggested that BMP signaling may actually have the opposite
effect of inducing muscle growth (27); specifically, this study
reported that expression of a constitutively active type I BMP
receptor (ALK3) can induce muscle growth and, conversely, that
overexpression of the BMP inhibitor, noggin, can cause muscle
atrophy not only in wild-type mice but also in Mstn−/− mice.
Nevertheless, we utilized mice carrying a floxed Bmpr2 allele
(28) to examine the possibility that MSTN and/or activin A may
signal through BMPRII in muscle. As shown in Table 1, mice in
which Bmpr2 was targeted in myofibers generally had lower
muscle weights than cre-negative mice, with the effects being
more pronounced in females (7 to 13% depending on the mus-
cle). Mice in which all three type II receptors (Bmpr2, Acvr2, and
Acvr2b) were targeted had muscle weights that were comparable
to those seen in mice in which just Acvr2 and Acvr2b were tar-
geted. These results imply that BMPRII activity in Acvr2/Acvr2b
mutant mice is unlikely to explain the difference seen between
Acvr2/Acvr2b targeted mice and Alk4/Alk5 targeted mice.
The effects of targeting Alk4 in combination with Alk5 were
striking not only in terms of their magnitude but also in terms of
the variability from mouse to mouse. As shown in Fig. 1C, the
weight of the gastrocnemius muscle was relatively consistent in
wild-type andMstn−/− mice as well as in mice in which both Acvr2
and Acvr2b were targeted in myofibers. In contrast, the weight of
the gastrocnemius muscle was highly variable in mice targeting
both Alk4 and Alk5 in myofibers, ranging from wild-type levels in
some mice to over five times wild-type levels in other mice. This
variability, which was also seen in the other muscles that were
examined, was unlikely to be due to one or more genetic mod-
ifiers segregating independently in these crosses, as we observed
similar distributions of effects both on a hybrid C57BL/6-129SvJ
and on a pure C57BL/6 background. Clearly, further investiga-
tion of the basis for this variability may provide important in-
sights into the control of muscle growth by this
signaling pathway.
Given that the results of these genetic studies clearly dem-
onstrated roles for both type II receptors and both type I re-
ceptors in mediating muscle growth, we sought to determine
whether all four possible combinations of type II and type I re-
ceptors (ACVR2/ALK4, ACVR2/ALK5, ACVR2B/ALK4, and
ACVR2B/ALK5) are utilized in vivo. Our strategy was to target
these receptors pairwise such that we would target one type II
receptor with one type I receptor. Our rationale was that by
targeting just one receptor of each type, only a single possible
type II/type I receptor combination would remain. For example,
by targeting both Acvr2b and Alk5, we examined the role of
ACVR2/ALK4, which is the only one of the four possible com-
binations whose function would be preserved in these mice. As
shown in Fig. 1D and Table 1, targeting both Acvr2b and Alk5
resulted generally in greater increases in muscle mass than tar-
geting either alone, implying that the ACVR2/ALK4 combina-
tion cannot be the sole one that is used in vivo; however, the
increases seen in these mice did not approach those seen either
in mice lacking both type II receptors or in mice lacking both
type I receptors, implying that the ACVR2/ALK4 combination
does play some role in signaling. By targeting all four pairwise
combinations in this manner, we found that all four type II/type I
combinations are functional in vivo and that no one combination
is sufficient to maintain wild-type signaling levels in the absence
of the other combinations. The most significant effects were
observed in mice in which we targeted both Acvr2 and Alk5,
which exhibited muscle mass increases of ∼40% in some muscles,
implying that the ACVR2B/ALK4 combination is the least im-
portant of the four combinations in limiting muscle growth; these
increases, however, were significantly less than those seen even
upon targeting both Acvr2 and Acvr2b, implying that the
ACVR2B/ALK4 combination is capable of playing some role in
regulating growth of myofibers.
Another receptor component that has been implicated in
MSTN signaling is cripto (Cfc1b), which is known to serve as a
coreceptor for certain ligands and to antagonize the activity of
other ligands (for review, see ref. 29). In this regard, one study
using C2C12 myoblasts reported that cripto is required for
MSTN signaling but inhibits activin A signaling (30); another
study, however, showed that during muscle regeneration in vivo,
cripto expressed by satellite cells acts to antagonize MSTN sig-
naling (31). To determine whether cripto plays a role in regu-
lating signaling in myofibers, we used the Myl1-cre transgene to
target Cfc1b either alone or in combination with each of the type
I or type II receptors. As shown in Fig. 1E and Table 2, we
observed no effect of targeting Cfc1b alone on muscle mass. We
did, however, see an effect of targeting Cfc1b in combination
with Acvr2, which resulted in small, but significant, increases in
muscle mass compared to targeting Acvr2 alone. This finding
implies that at least some signaling through ACVR2B requires
cripto function, although the fact that the effects seen in these
mice were substantially lower than those seen in mice in which
we targeted both Acvr2 and Acvr2b implies that most signaling
through ACVR2B in myofibers does not require cripto. Signifi-
cantly, we observed no consistent effect of targeting Cfc1b in
combination with Alk5, implying that cripto expressed in myo-
fibers is not required for signaling through ALK4 in myofibers,
which contrasts with what has been reported in cell culture
studies (30).
In previous studies, we showed that the function of MSTN in
limiting muscle growth is redundant with that of at least one
other TGF-β family member (13, 14), and several studies have
implicated activin A as at least one of the key cooperating li-
gands (15, 16). To determine whether particular receptor com-
ponents are used exclusively by particular ligands, we analyzed
the effect of targeting each of the type II and type I receptors in
combination with Mstn. Targeting Mstn specifically in myofibers
utilizing mice carrying a floxed Mstn allele that we had generated
previously (32) resulted in a reduction of Mstn mRNA in muscle
by 95 to 99% and a reduction in circulating levels of MSTN
protein by 92 and 85% in females and males, respectively (SI
Appendix, Fig. S3). We presume that the residual expression
represents MSTN made by type I fibers, and although we cannot
rule out the possibility of non–muscle-derived MSTN contrib-
uting significantly to the circulating pool, these data are consis-
tent with myofibers being at least the predominant (if not sole)
source of circulating MSTN protein.
Targeting Mstn in myofibers led to increases in muscle mass of
55 to 64% and 49 to 59% in females and males, respectively,


























depending on the specific muscle (Fig. 1F and Table 3). Our
strategy was to determine whether targeting a receptor compo-
nent in addition to Mstn would result in further increases in
muscle mass. Our rationale was that by simultaneously targeting,
for example, both Mstn and one type II (or type I) receptor, we
would be able to determine the contribution of the other type II
(or type I) receptor in mediating activin A signaling. In general,
targeting a given receptor in combination with Mstn led to
greater increases in muscle mass compared to targeting Mstn
alone. Of the combinations that we tested, the greatest statisti-
cally significant effects were seen in females in which Mstn was
targeted along with Acvr2b or Alk4. These results imply that
Table 2. Muscle weights in Cfc1b-targeted mice
Acvr2 Acvr2b Alk4 Alk5 Cfc1b cre n Pectoralis, mg Triceps, mg Quadriceps, mg Gastrocnemius, mg
Males
+/+ +/+ +/+ +/+ fl/fl − 11 64.6 ± 2.0 90.7 ± 3.5 176.1 ± 6.0 124.6 ± 3.6
+/+ +/+ +/+ +/+ fl/fl + 20 63.7 ± 1.5 90.4 ± 2.1 171.9 ± 3.9 121.3 ± 2.6
fl/fl +/+ +/+ +/+ fl/fl − 10 71.4 ± 2.4 96.1 ± 2.9 184.6 ± 6.2 134.7 ± 3.5
fl/fl +/+ +/+ +/+ fl/fl + 18 68.3 ± 2.3 99.6 ± 2.9 201.6 ± 6.8 150.3 ± 4.5*
+/+ fl/fl +/+ +/+ fl/fl − 15 73.0 ± 2.2 97.3 ± 3.4 187.3 ± 7.0 136.5 ± 4.3
+/+ fl/fl +/+ +/+ fl/fl + 8 78.6 ± 4.6 106.9 ± 4.4 208.1 ± 9.5 150.1 ± 5.7
+/+ +/+ fl/fl +/+ fl/fl − 13 76.7 ± 1.5 97.1 ± 1.9 195.1 ± 4.1 140.7 ± 2.4
+/+ +/+ fl/fl +/+ fl/fl + 16 73.5 ± 1.4 97.4 ± 1.8 198.2 ± 4.2 140.3 ± 2.5
+/+ +/+ +/+ fl/fl fl/fl − 17 62.6 ± 1.4 83.5 ± 1.7 164.1 ± 2.5 110.8 ± 1.3
+/+ +/+ +/+ fl/fl fl/fl + 17 69.8 ± 2.3† 92.4 ± 2.6* 184.9 ± 5.1‡ 128.6 ± 3.4‡
Females
+/+ +/+ +/+ +/+ fl/fl − 14 42.1 ± 1.2 66.4 ± 1.3 129.1 ± 2.7 89.5 ± 2.2
+/+ +/+ +/+ +/+ fl/fl + 17 41.6 ± 1.1 65.6 ± 1.7 126.5 ± 3.4 88.9 ± 2.5
fl/fl +/+ +/+ +/+ fl/fl − 11 43.4 ± 1.8 67.5 ± 2.0 131.9 ± 4.5 95.3 ± 3.0
fl/fl +/+ +/+ +/+ fl/fl + 11 45.9 ± 1.0 75.5 ± 1.3* 153.4 ± 3.8* 113.1 ± 3.4‡
+/+ fl/fl +/+ +/+ fl/fl − 6 47.5 ± 1.4 70.8 ± 2.4 139.7 ± 2.9 98.5 ± 2.5
+/+ fl/fl +/+ +/+ fl/fl + 5 50.8 ± 2.6 77.0 ± 2.3 151.6 ± 2.6* 106.0 ± 2.0†
+/+ +/+ fl/fl +/+ fl/fl − 20 50.6 ± 0.9 73.6 ± 1.2 147.5 ± 2.1 105.1 ± 1.6
+/+ +/+ fl/fl +/+ fl/fl + 12 53.4 ± 1.0† 75.9 ± 1.5 159.8 ± 2.7‡ 111.1 ± 1.0*
+/+ +/+ +/+ fl/fl fl/fl − 26 44.5 ± 0.8 68.2 ± 1.1 128.8 ± 2.2 85.6 ± 1.5
+/+ +/+ +/+ fl/fl fl/fl + 17 47.7 ± 1.5 71.4 ± 1.9 141.4 ± 3.9* 96.9 ± 2.6‡
*P < 0.01 vs. cre−.
†P < 0.05 vs. cre−.
‡P < 0.001 vs. cre−.
Table 3. Muscle weights in Mstn-targeted mice
Acvr2 Acvr2b Alk4 Alk5 Mstn cre n Pectoralis, mg Triceps, mg Quadriceps, mg Gastrocnemius, mg
Males
+/+ +/+ +/+ +/+ fl/fl − 21 69.3 ± 1.8 92.4 ± 1.9 184.3 ± 3.6 132.6 ± 3.0
+/+ +/+ +/+ +/+ fl/fl + 21 103.3 ± 4.2* 141.9 ± 5.1* 293.4 ± 7.7* 209.6 ± 4.8*
fl/fl +/+ +/+ +/+ fl/fl − 16 68.4 ± 0.7 92.3 ± 1.4 177.0 ± 2.8 129.8 ± 1.4
fl/fl +/+ +/+ +/+ fl/fl + 15 105.3 ± 6.1* 157.6 ± 8.2* 324.0 ± 15.5* 238.5 ± 11.1*,†
+/+ fl/fl +/+ +/+ fl/fl − 15 65.9 ± 2.8 88.5 ± 4.1 168.3 ± 5.8 122.7 ± 4.2
+/+ fl/fl +/+ +/+ fl/fl + 14 115.6 ± 5.5* 158.9 ± 6.6*,† 298.7 ± 8.3* 217.6 ± 5.8*
+/+ +/+ fl/fl +/+ fl/fl − 18 70.8 ± 1.2 99.4 ± 1.7 185.7 ± 2.9 130.6 ± 1.7
+/+ +/+ fl/fl +/+ fl/fl + 20 113.0 ± 5.4* 171.9 ± 9.0*,‡ 337.5 ± 18.6*,† 233.5 ± 10.6*
+/+ +/+ +/+ fl/fl fl/fl − 13 68.9 ± 1.3 95.2 ± 1.6 172.8 ± 2.0 125.6 ± 1.9
+/+ +/+ +/+ fl/fl fl/fl + 19 114.3 ± 3.7* 160.7 ± 4.6*,‡ 296.3 ± 6.7* 218.0 ± 3.9*
Females
+/+ +/+ +/+ +/+ fl/fl − 15 47.9 ± 1.4 71.3 ± 1.6 142.0 ± 3.6 99.2 ± 2.2
+/+ +/+ +/+ +/+ fl/fl + 17 74.4 ± 2.1* 116.5 ± 2.4* 227.6 ± 4.9* 156.8 ± 2.8*
fl/fl +/+ +/+ +/+ fl/fl − 18 48.1 ± 0.9 72.5 ± 1.3 141.4 ± 2.0 104.3 ± 1.9
fl/fl +/+ +/+ +/+ fl/fl + 22 73.2 ± 2.8* 123.0 ± 5.7* 251.0 ± 11.4* 180.2 ± 8.2*,†
+/+ fl/fl +/+ +/+ fl/fl − 19 49.5 ± 2.1 71.3 ± 2.0 135.2 ± 3.6 98.2 ± 2.9
+/+ fl/fl +/+ +/+ fl/fl + 18 83.2 ± 2.9*,‡ 128.1 ± 3.7*,‡ 241.2 ± 5.5*,† 171.5 ± 4.3*,‡
+/+ +/+ fl/fl +/+ fl/fl − 13 51.8 ± 1.1 73.5 ± 1.5 140.2 ± 3.9 101.2 ± 2.7
+/+ +/+ fl/fl +/+ fl/fl + 21 82.4 ± 2.5*,† 141.8 ± 3.1*,§ 279.6 ± 6.6*,§ 188.7 ± 4.7*,§
+/+ +/+ +/+ fl/fl fl/fl − 12 50.2 ± 2.2 73.5 ± 2.0 136.1 ± 4.5 100.8 ± 2.6
+/+ +/+ +/+ fl/fl fl/fl + 6 71.2 ± 4.4* 113.7 ± 4.6* 215.7 ± 11.4* 150.7 ± 9.0*
*P < 0.001 vs. cre−.
†P < 0.05 vs. Mstn fl/fl, cre+.
‡P < 0.01 vs. Mstn fl/fl, cre+.
§P < 0.001 vs. Mstn fl/fl, cre+.











































ACVR2B and ALK4 (and perhaps the combination of these two
receptors) are likely to be utilized by activin A for signaling in
myofibers more than ACVR2 and ALK5; however, these addi-
tional increases seen upon targeting a given receptor in combi-
nation with Mstn were still relatively small compared to the
dramatic increases that we have observed in previous studies in
which we targeted multiple ligands simultaneously (13, 14),
suggesting that the ACVR2B/ALK4 combination is unlikely to
be the sole receptor combination that is utilized by activin A in
myofibers in vivo.
The findings presented here as well as our prior study (23)
demonstrate that myofibers are the primary cellular targets for
signaling by MSTN/activin A with respect to the regulation of
muscle growth by these ligands. A variety of studies, however,
have reported additional effects of genetic and pharmacological
targeting of MSTN/activin A on other physiological processes.
These findings have raised the question as to whether these other
physiological effects reflect loss of MSTN/activin A signaling to
other cell types and tissues or whether these are indirect effects
resulting from inhibition of signaling to myofibers. In this re-
spect, both MSTN and activin A are known to circulate in the
blood, and these receptors are expressed by multiple cell types in
multiple tissues. Because we were able to generate significant
effects on muscle growth by targeting receptors in myofibers, we
investigated other physiological effects in these targeted mice to
attempt to address this fundamental question. For these studies,
we focused on mice in which we targeted the two type II re-
ceptors, ACVR2 and ACVR2B. Although the magnitude of the
muscle mass increases was significantly larger in mice in which
the two type I receptors were targeted, mice lacking ACVR2 and
ACVR2B exhibited a much more consistent phenotype (as dis-
cussed above), making these studies easier to interpret.
In one set of studies, we examined the effect of targeting Acvr2
and Acvr2b in myofibers on muscle regeneration. A large number
of studies have shown beneficial effects of targeting MSTN sig-
naling on muscle regeneration in the setting of muscle degen-
eration or following muscle injury (for review, see ref. 1). A key
question in this regard is whether these beneficial effects reflect
inhibition of direct MSTN signaling to muscle satellite cells or
whether inhibition of MSTN signaling to myofibers can enhance
satellite cell activation and/or function in the setting of muscle
degeneration or injury. To this end, we induced muscle damage
and regeneration via injection of barium chloride intramuscu-
larly in Acvr2 fl/fl-Acvr2b fl/fl mice carrying the Myl1-cre trans-
gene compared to mice lacking Myl1-cre. We examined the
injured muscles at 5 and 21 d postinjury (DPI) to assess the effect
of myofiber-specific knockout of Acvr2 and Acvr2b on muscle
regeneration. As shown in Fig. 2 A and B, we found that fiber
cross-sectional area (CSA) was significantly greater in uninjured
muscles lacking both Acvr2 and Acvr2b. In contrast, no differ-
ences in fiber CSA were observed in injured muscles assessed at
5 and 21 DPI. We next examined the effect of targeting Acvr2
and Acvr2b in myofibers on the expansion and self-renewal of
satellite cells during the regenerative process. We found no
differences in the number of Pax7+ cells, either at 5 or 21 DPI,
between Acvr2 fl/fl-Acvr2b fl/fl mice carrying the Myl1-cre trans-
gene compared to mice lacking Myl1-cre (Fig. 2C). These results
suggest that loss of Acvr2 and Acvr2b in the muscle fibers results
in no significant alteration in satellite cell function during muscle
regeneration.
Another physiological consequence of MSTN loss or inhibi-
tion in addition to stimulating muscle fiber growth is an overall
effect on fat and glucose metabolism. We showed previously that
Mstn−/− mice exhibit a significant suppression of fat accumula-
tion and improved glucose metabolism in an otherwise wild-type
background as well as in ob/ob and agouti lethal yellow back-
grounds (33). Beneficial metabolic effects have also been de-
scribed in mice treated with MSTN inhibitors (34–37). A key
question is whether these beneficial effects on fat accumulation
and glucose metabolism are the result of inhibition of MSTN
signaling to myofibers, leading to muscle growth, or whether they
reflect lack of direct MSTN signaling to other cell types and
tissues, including adipose tissue. In previous studies, we showed
that differences in fat accumulation between Mstn−/− and wild-
type C57BL/6 mice become more pronounced as mice age (33).
Hence, we focused our initial analysis on 1-y-old mice. By dual-
energy X-ray absorptiometry (DXA) analysis, total body fat
content in 1-y-old Mstn−/− mice was reduced to less than one-
third that of wild-type C57BL/6 mice, with a concomitant re-
duction in percent body fat (Fig. 3). Similarly, total fat content
and percent body fat were reduced in Acvr2 fl/fl-Acvr2b fl/fl mice
carrying the Myl1-cre transgene compared to mice lacking Myl1-
cre, with the effects being more pronounced in females. Con-
sistent with these differences in body fat content, serum leptin
levels were also reduced in Mstn−/− mice as well as in Acvr2 fl/fl-
Acvr2b fl/fl mice carrying the Myl1-cre. Hence, the reduced fat
mass seen upon loss of MSTN signaling is likely an indirect effect
of increased muscling in these mice. Fasting glucose levels were
generally similar among the different genotypes at this age, al-
though we did observe statistically significant lower fasting glu-
cose levels in Acvr2 fl/fl-Acvr2b fl/fl female mice carrying the
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Fig. 2. Lack of effect of targeting Acvr2 and Acvr2b in myofibers on muscle
regeneration following chemical injury. (A–C) Distribution of myofiber CSAs
(A), mean CSAs (B), and number of Pax7+ cells (C) in Acvr2 fl/fl, Acvr2b fl/fl
mice with or without Myl1-cre either uninjured or 5 or 21 DPI.


























importantly, these normal to lower fasting glucose levels were
maintained despite significantly lower fasting insulin levels both
in Mstn−/− mice compared to wild-type C57BL/6 mice and in
Acvr2 fl/fl-Acvr2b fl/fl mice carrying the Myl1-cre transgene
compared to mice lacking Myl1-cre, with the effect again being
more pronounced in females.
We also examined the effects of placing these mice on high fat
diets. For these studies, we analyzed younger mice (12 wk of age)
of both sexes. Although we generally observed similar effects in
both males and females, the effects were more pronounced in
males. As shown in Fig. 4A, Mstn−/− mice gained much less
weight than wild-type mice throughout an 8-wk period on a high-
fat diet. Similarly, Acvr2 fl/fl-Acvr2b fl/fl mice carrying the Myl1-
cre transgene gained significantly less weight on a high-fat diet
than mice lacking cre. We also observed differences in these
mice in terms of glucose metabolism when maintained on a high-
fat diet. Fasting glucose levels were lower in Mstn−/− mice
compared to wild-type mice, and this lowering of fasting glucose
levels was also seen in Acvr2 fl/fl-Acvr2b fl/fl-Myl1-cre mice
compared to mice lacking cre (Fig. 4B). In glucose-tolerance
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Fig. 3. Total body fat content by DXA analysis, plasma leptin levels, fasting
blood glucose levels, and fasting plasma insulin levels in 1-y-old mice lacking
MSTN and mice in which both type II receptors were targeted in myofibers.
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Fig. 4. Effect of a high-fat diet on Mstn−/− mice and mice in which Acvr2
and Acvr2b have been targeted in myofibers. (A) Weight gain in male mice
placed on a high-fat diet starting at 12 wk of age. (B and C) Fasting blood
glucose levels (B) and GTTs (C) in 12 wk-old male mice on standard diets or
after placement on a high-fat diet for 4 wk. In C, the numbers of mice in
each group are the same as shown in A.











































Acvr2b fl/fl-Myl1-cre mice had glucose levels that trended lower,
although only one time point reached statistical significance
(Fig. 4C). Following 4 wk on a high-fat diet, however, these
differences were accentuated, with Acvr2 fl/fl-Acvr2b fl/fl-Myl1-cre
mice having significantly lower glucose levels, particularly in the
later time points. Taken together, these results clearly demon-
strate that targeting this signaling pathway specifically in myofibers
can lead to beneficial effects on fat and glucose metabolism.
Finally, we examined effects on bone. Prior studies have
identified effects on bone density and structure in Mstn−/− mice
(38). In addition, we (13, 24, 39) and others (35, 40) have
reported that administration of a soluble form of the activin type
IIB receptor (ACVR2B/Fc) systemically to mice can increase not
only muscle mass but also bone mineral density. At least part of
this effect is due to inhibition of signaling directly to bone (likely
by activin A), as targeting Acvr2 and Acvr2b in osteoblasts is
sufficient to increase bone density in vivo (24). It is also possible,
however, that some of the effects on bone may be indirect as a
result of increased mechanical load on the bone due to enhanced
muscle mass resulting from inhibition of signaling to myofibers.
To test the role of increased muscle mass on bone, we compared
bones of mice in which we targeted Acvr2 and Acvr2b in myo-
fibers not only to bones of wild-type and cre-negative mice but
also to those of mice receiving the ACVR2B/Fc decoy receptor.
We reported previously that systemic administration of the
ACVR2B/Fc decoy receptor to mice can induce rapid and sig-
nificant muscle growth, and at the dose that we used in this study,
individual muscle weights increased by about 40 to 50% over the
5-wk treatment period (SI Appendix, Fig. S4). Administration of
the decoy receptor to wild-type mice also resulted in significant
increases in bone density, as assessed by DXA analysis, with bone
mineral density being ∼15% higher in treated compared to un-
treated mice after 5 wk of treatment with ACVR2B/Fc (Fig. 5A).
This bone anabolic effect was confirmed by micro-computed
tomography (microCT) analysis (Fig. 5 B and C and SI Appen-
dix, Tables S1 and S2), which showed dramatic increases in bone
volume, bone surface, and trabecular thickness and number in
both the femur and L4 and L5 vertebrae in ACVR2B/Fc-treated
mice. In contrast, bones of mice in which Acvr2 and Acvr2b were
targeted in myofibers exhibited no statistically significant dif-
ferences in any of these parameters. These results demonstrate
that increasing muscle mass per se by targeting these receptors
specifically in myofibers does not lead to corresponding increases
in bone density and that the effect of ACVR2B/Fc in increasing
bone density is almost certainly due to inhibition of direct sig-
naling to bone, likely by activin A.
Discussion
Like other TGF-β family members, MSTN signals by utilizing a
two-component receptor mechanism. Using biochemical ap-
proaches, we previously showed that MSTN is capable of binding
initially to either of the two activin type II receptors, ACVR2
(also called ACVR2A or ActRIIA) and ACVR2B (also called
ActRIIB) (18). Because MSTN appeared to bind ACVR2B with
higher affinity than ACVR2 and because overexpression of a
truncated form of ACVR2B (lacking the cytoplasmic kinase
domain) in skeletal muscle could phenocopy the Mstn
loss-of-function mutation in terms of increased muscle mass, it
was presumed that ACVR2B is the primary type II receptor
utilized by MSTN in vivo. In a follow-up genetic study, however,
we showed that mice null for either Acvr2 or Acvr2b exhibit in-
creased muscling and that these two receptors are partially
functionally redundant (13). One limitation of that study was
that examining the consequence of complete loss of both re-
ceptors was not possible using the deletion alleles for these genes
because mice completely lacking both receptors are not viable
(22). In order to circumvent this lethality issue, we sought to
target these receptors specifically in myofibers, as we had shown
that myofibers are direct targets for MSTN signaling and that
blocking signaling in myofibers is sufficient to induce muscle
growth (23). In the studies presented here, we targeted these
receptors by crossing in a myosin light chain-cre (Myl1-cre)
transgene (25), which is expressed specifically by myofibers, into
mice that we had generated carrying floxed alleles for Acvr2 and
Acvr2b. We show that targeting Acvr2 and Acvr2b individually
results in small, although significant, increases in muscle mass
but that simultaneously targeting both type II receptors leads to
much more dramatic effects, demonstrating conclusively that
both receptors function to suppress muscle growth and that the
two receptors are functionally redundant in this regard.
The identification of ACVR2 and ACVR2B as MSTN re-
ceptors led to two strategies to develop therapeutics targeting
MSTN signaling to treat patients with muscle loss or degenera-
tion. One approach was to generate a soluble form of ACVR2B
in which the ligand-binding domain was fused to an immuno-
globulin Fc domain (13, 41). Indeed, this decoy receptor
(ACVR2B/Fc) is still the most potent agent described to date in
terms of its ability to promote muscle growth; in fact, just two
injections of this decoy receptor at high doses to mice can cause
greater than 50% muscle growth throughout the body in just 2
wk (13). Although this effect of the decoy receptor has been
widely cited in the literature as evidence that ACVR2B is the
primary receptor utilized by MSTN in vivo, it is important to
note that because this decoy receptor is a ligand trap, it is ca-
pable of blocking signaling of ligands through other receptors as
well. A second approach, which was taken by Novartis, was to
develop a monoclonal antibody targeting ACVR2B directly
(42–46). Although the initial publication of this monoclonal
antibody (bimagrumab, or BYM338) reported that it had over
200-fold higher affinity for ACVR2B compared to ACVR2,
subsequent studies showed that by X-ray crystallography analysis,
BYM338 is capable of blocking the ligand-binding domain of
both receptors (47). They further showed that highly specific
monoclonal antibodies directed against each receptor (with no
cross-reactivity to the other receptor) had an additive effect in terms
of stimulating muscle growth when given to mice. Hence, these
pharmacologic studies taken together with our genetic studies
presented here demonstrate conclusively that both ACVR2 and
ACVR2B play critical roles in regulating muscle growth.
Binding of MSTN to the type II receptors then leads to en-
gagement of the two type I receptors, ALK4 and ALK5 (18, 21).
Although a number of studies have examined the roles of these
receptors in cell culture systems, very few studies have addressed
the functions of these receptors in vivo with respect to control of
muscle growth. Some of these in vivo studies reached somewhat
contradictory conclusions. In particular, whereas small-molecule
inhibitors of ALK4/5 were shown to induce muscle fiber hyper-
trophy in both wild-type and dystrophic mice (48) as well as to
preserve muscle mass in a cancer cachexia model (49), delivery
of an antisense oligonucleotide directed against Alk4 had the
opposite effect, leading to a reduction in muscle mass (50). Here,
we took a genetic approach in which we used the Myl1-cre
transgene to target floxed Alk4 and Alk5 alleles in myofibers.
We show that targeting Alk4 alone has no effect on muscle mass
and that targeting Alk5 alone has a small, although significant,
effect. Targeting both type I receptors simultaneously, however,
leads to dramatic increases in muscle size. These increases are
substantially higher than those seen upon targeting ACVR2 and
ACVR2B, raising the possibility that yet another type II receptor
may also be involved in regulating muscle mass. We showed that
targeting BMPR2 along with ACVR2 and ACVR2B does not
cause further increases in muscle mass, leaving TGFBR2 as the
only remaining candidate, although no binding of either MSTN
or activin A to TGFBR2 has been reported.
These increases seen upon targeting both Alk4 and Alk5 even
surpassed the doubling of muscle mass seen in mice completely


























lacking MSTN and are more reminiscent of the quadrupling of
muscle mass seen in Mstn−/− mice that also carry a transgene
overexpressing the MSTN inhibitor, follistatin, in skeletal muscle
(14). The ability of follistatin as well as the ACVR2B/Fc decoy
receptor (13) to induce further muscle growth even in Mstn−/−
mice showed that at least one other TGF-β family member be-
sides MSTN must also play an important role in suppressing
muscle growth, and subsequent studies have identified activin A
as the key cooperating ligand (15, 16). The dramatic increases in
muscle growth that we obtained by targeting both Alk4 and Alk5
in myofibers suggests that these receptors must be involved in
mediating signaling by both MSTN and activin A to myofibers.
Furthermore, by simultaneously targeting different combinations
of type I and type II receptors and by simultaneously targeting
Mstn with each type I and type II receptor, we were able to in-
vestigate whether specific receptor combinations are utilized by
specific ligands. Although we detected some quantitative dif-
ferences targeting different combinations, the overall conclusion
from all of these studies is that muscle mass is regulated by at
least two ligands (MSTN, activin A) signaling directly to myo-
fibers through two type II (ACVR2, ACVR2B) and two type I
(ALK4, ALK5) receptors, with all ligand and receptor combi-
nations being utilized in a highly redundant manner. These
findings suggest that in order to generate maximal effects on
muscle growth, it is essential that any therapeutic strategy be
capable of targeting either multiple receptor components si-
multaneously, such as with BYM338, or multiple ligands simul-
taneously, such as with the ACVR2B/Fc decoy receptor.
These studies also demonstrate conclusively that myofibers are
the direct targets for MSTN and activin A signaling with respect
to control of muscle growth. Given that we were able to generate
substantial effects on muscle mass by blocking MSTN/activin
signaling just in myofibers, we used this experimental approach
to investigate other physiological effects in these mice. In par-
ticular, previous studies using Mstn−/− mice have identified ef-
fects of MSTN loss on other tissues besides skeletal muscle,
raising the question as to whether MSTN is capable of signaling
directly to these other tissues in vivo or whether these are indi-
rect effects of lack of MSTN signaling to skeletal muscle. In the
studies presented here, we were able to distinguish direct versus
indirect effects by blocking MSTN and activin A signaling just in
myofibers. Although targeting the two type I receptors generated
the greatest effects on muscle mass, the phenotype was highly var-
iable in these mice, and we therefore decided to focus instead on
mice in which we targeted the two type II receptors, ACVR2 and
ACVR2B, for which the phenotype was much more consistent.
One tissue other than skeletal muscle known to be affected in
Mstn−/− mice is adipose tissue. We showed previously that
Mstn−/− mice have a reduction in fat accumulation, particularly
as a function of age, not only in a wild-type background but also
in ob/ob and agouti lethal yellow backgrounds, as well as benefi-
cial effects on glucose metabolism (33). Subsequent studies
showed that loss or inhibition of MSTN can increase skeletal
muscle glucose uptake and energy expenditure and protect
against high-fat diet-induced weight gain as well as glucose in-
tolerance (34–37). A key question is whether all of these effects
on adipose tissue and glucose metabolism reflect loss of MSTN
signaling to skeletal muscle or whether some of these effects
reflect loss of MSTN signaling to other tissues. In this regard, a
previous study showed that mice overexpressing a truncated form
of ACVR2B in skeletal muscle (18) also exhibit some of the
metabolic effects seen in Mstn−/− mice (51); however, because
this truncated receptor could act as a ligand trap, one could not
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Fig. 5. Lack of bone effects of targeting Acvr2 and Acvr2b in myofibers. (A, Top) DXA analysis of wild-type C57BL/6 mice either uninjected (n = 9) or injected
weekly with the ACVR2B/Fc decoy receptor at a dose of 10 mg/kg (n = 8) starting at 10 wk of age. (A, Bottom) DXA analysis of Acvr2 flox/flox, Acvr2b flox/flox
mice with (n = 8) and without (n = 12) the Myl1-cre transgene at the same ages as in A, Top. *P < 0.05, **P < 0.001. (B) MicroCT images of femurs taken from
these same mice at 16 wk of age. (C) Bone volume/total volume fraction, trabecular thickness, trabecular number, apparent density, and cortical thickness of
femurs and L4 and L5 vertebrae determined by microCT analysis in these mice at 16 wk of age. Numbers of mice in each group are shown underneath
the bars.











































receptor may be to act as a sink by binding MSTN produced by
skeletal muscle and thereby leading to inhibition of MSTN sig-
naling not only to muscle but also to other tissues. Indeed,
among the cell types known to be responsive to MSTN in cell
culture are adipocytes (52). Moreover, although Mstn is
expressed at low levels in adipose tissue in wild-type mice (2),
Mstn expression is significantly up-regulated in both subcutane-
ous and visceral fat in ob/ob mice (53). To address whether the
effects on adipose tissue and glucose metabolism seen in Mstn−/−
mice reflect direct or indirect effects of MSTN loss, we analyzed
the metabolic effects of targeting Acvr2 and Acvr2b in myofibers.
We show that these mice, like Mstn−/− mice, have reduced
overall body fat, lower serum leptin levels, and reduced weight
gain on a high-fat diet. These receptor-targeted mice also have
lower fasting blood glucose despite having lower fasting insulin
levels and are able to maintain lower glucose levels in GTTs.
These findings demonstrate that these metabolic effects as well
as the suppression of fat accumulation can be achieved by inhi-
bition of signaling solely in myofibers.
Another tissue known to be affected in Mstn−/− mice is bone.
In particular, Mstn−/− mice have been reported to have a gen-
eralized increase in bone mineral density at many sites, including
femurs (38, 39). A key question raised by these findings is
whether this increased bone mineral density results from in-
creased mechanical load on the bones due to the hyper-
muscularity in these mice or rather from loss of MSTN signaling
directly to bone. In this regard, MSTN has been reported to be
capable of acting directly on bone-progenitor cells in vitro to
regulate cell differentiation (54). It is also known that MSTN
inhibitors, like follistatin and the ACVR2B/Fc decoy receptor,
can have significant effects on bone repair and bone density
in vivo (39, 40, 55, 56), but because these inhibitors can also
block activin signaling, the identities of the key ligands being
blocked in these studies is not clear. Similarly, it is known that
targeting activin type II receptors in osteoblasts in vivo can also
increase bone density (24), but this effect likely reflects inhibition
of signaling by activin rather than by MSTN. In order to deter-
mine the contribution of increased skeletal muscle mass on bone
density, we analyzed the bones of mice in which we targeted
Acvr2 and Acvr2b in myofibers. Here, we show that whereas
systemic administration of the ACVR2B/Fc decoy receptor to
wild-type mice can induce dramatic increases in both muscle
mass and bone mineral density, increasing muscle mass by tar-
geting these receptors in myofibers has no effect on bone mineral
density either in the femurs or in the lumbar vertebrae. These
findings demonstrate that the effect of the ACVR2B/Fc decoy
receptor on increasing bone mass is almost certainly due to in-
hibition of signaling by TGF-β–related ligands directly to bone
and, furthermore, that increasing muscle mass by up to even 60
to 70% in the hindlimbs was not sufficient to increase bone
density either through increased mechanical load on the bones
or through the release of hypothetical secondary mediators
by muscle.
Finally, we showed that blocking signaling specifically in
myofibers also has no effect on muscle regeneration, implying
that the effects of MSTN loss or inhibition observed in prior
studies likely reflect inhibition of signaling directly to satellite
cells. Although a formal demonstration of the role of signaling in
satellite cells will require targeting these receptors specifically in
that cell population, these findings suggest that MSTN and/or
activin A signal to multiple cell types within skeletal muscle and
play at least two distinct roles in regulating muscle homeostasis,
one to regulate myofiber growth and another to regulate muscle
regeneration following injury.
Materials and Methods
All animal experiments were carried out in accordance with protocols that
were approved by the Institutional Animal Care and Use Committees at The
Jackson Laboratory, University of Connecticut School of Medicine, and Johns
Hopkins University School of Medicine. Mice carrying floxed alleles for Acvr2
(24), Acvr2b (23), Alk5 (26), Bmpr2 (28), Cfc1b (57), and Mstn (32) have been
described previously. To generate Alk4 conditional knockout mice, we
generated a targeting construct in which we flanked exons 2 to 3 with LoxP
sites (SI Appendix, Fig. S2). Following electroporation of the targeting con-
struct into embryonic stem (ES) cells, ES cell colonies carrying the homo-
logously targeted allele were injected into blastocysts, and mice generated
from these blastocysts were bred to identify those exhibiting germline
transmission of the targeted allele. Offspring from these matings were then
bred with EIIa-Cre transgenic mice (58) in order to delete the neomycin re-
sistance cassette in the germline. From these crosses, we obtained mice
carrying an Alk4 flox allele lacking the NEO cassette.
For measurement of muscle weights, individual muscles were dissected
from both sides of 10-wk-old mice, and the average weight was used for
each muscle. Circulating MSTN levels were determined on acid-activated
serum samples by enzyme-linked immunosorbent assay using the R&D Sys-
tems DGDF80 kit. To induce muscle damage and regeneration, 50 μL of 1.2%
barium chloride (wt/vol) (Sigma) was delivered to the right tibialis anterior
(TA) muscle over 10 intramuscular punctures. The left TA served as the un-
injured control. TA muscles were harvested either 5 or 21 DPI, mounted in
optimal cutting temperature compound, and frozen in thawing isopentane.
Serial sections (8 μm) were cut transversely through the belly of the TA
muscle using a refrigerated cryostat. TA sections were immunoreacted to
laminin (Sigma L9393) and Pax7 (DSHB) applied with the M.O.M Basic Kit
(Vector Laboratories). Sections were then counterstained with DAPI to vi-
sualize nuclei and imaged with a Zeiss Observer Z1 microscope with a color
camera (Hammatsu Orca-ER camera) controlled by Volocity software (Per-
kinElmer). Images were then quantified using ImageJ software.
Live animal imaging was performed using a Piximus dual-energy X-ray
absorptiometer. GTTs were performed by giving mice an intraperitoneal
injection of 1 g glucose/kg body weight following a 6-h fast. Mice were then
placed on a 60 kcal% fat diet (D12492; Research Diets, Inc.) for 8 wk, with a
repeat GTT being performed after 4 wk. The ACVR2B/Fc decoy receptor was
expressed in Chinese hamster ovary cells, purified from the conditioned
medium using a protein A Sepharose column, and administered intraperi-
toneally at a dose of 175 μg per injection. For microCT analysis, the left fe-
mur and lumbar vertebrae were placed in 70% ethanol. MicroCT was
performed in a Scanco MicroCT40 at 8-μm3 resolution. Samples were scan-
ned in 70% ethanol 55 kVp, 145-μA intensity, 300 ms. The instrument is
calibrated weekly using Scanco phantoms, and all scans passed routine
quality-control verification. Analysis of femurs and vertebrae was conducted
using standard protocols, with a lower threshold of 2,485 Hounsfield units
(HU) for femoral trabeculae, 4,932 HU for femoral cortex, and 3,078 HU for
vertebral trabeculae (59). Surface renderings were generated corresponding
to each of these thresholds.
Data Availability. All study data are included in the article and SI Appendix.
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